Me Today Surpasses Revenue Targets with 36% Growth and Secures $1.59m Capital Injection

Revenue Growth Outpaces Expectations Amid Strategic Expansion

Me Today Limited (NZX:MEE) has reported a robust 36% increase in group gross revenue for the year ended 30 June 2026, reaching $7.96 million and comfortably beating its May guidance of $7.4 million. This growth was fuelled primarily by surging sales in New Zealand and China, alongside the rollout of a new distribution agreement spanning key Southeast Asian markets.

The company’s total external revenue, after deducting marketing costs paid to customers, also rose by 36% to $6.53 million, signalling strong underlying demand for its health and wellness products. While Me Today remains loss-making at the EBITDA level, the operating loss improved significantly by 43% to $1.23 million, ahead of the forecast loss of less than $1.6 million.

Capital Commitment from Largest Shareholders Secures FY27 Funding

Backing this growth trajectory, Me Today secured irrevocable commitments from its two largest shareholders, entities linked to Chairman Grant Baker and CEO Stephen Sinclair, to exercise a minimum of 26.5 million Series 1 Warrants in October 2026. This will inject at least $1.59 million in new capital at an exercise price of 6 cents per warrant, providing crucial funding to sustain ongoing product development, marketing, and international expansion.

The total Series 1 Warrants on issue stand at 47.26 million, with full exercise potentially raising $2.84 million. While other warrant holders may also exercise their rights, the company emphasises that these decisions remain at the discretion of individual investors.

New Zealand and China Drive Market Momentum

New Zealand remains Me Today’s core market, with a strategic planogram introduced in March 2026 boosting in-store brand visibility. Retail scan data from the largest NZ retail partner showed an 85% increase in sales over the 12 months to August 2026 compared to the prior year. The company also launched 15 new products during FY26, including a new Potent Herbal liquid range, capsule and resin formats, and its first powdered supplements. Another 20 products are slated for release before year-end.

Meanwhile, the China licensing partnership continues to gain traction. Licence fee revenue for the year to March 2026 more than doubled to $1.1 million, reflecting a shift to a revenue-based fee structure. The Chinese partner has increased its ownership stake in the Me Today China trademark to 40% after hitting revenue milestones, expanding the brand’s footprint through live-streaming and direct-to-consumer channels across multiple online platforms.

Southeast Asia Distribution Agreement Opens New Markets

Me Today has inked an exclusive distribution deal covering Singapore, Malaysia, Thailand, and Vietnam, with minimum sales targets over five years. The launch began in Singapore with initial orders fulfilled between June and August 2026. Malaysia’s market entry is expected in 2027, with Thailand and Vietnam progressing through regulatory registration.

Additional markets include the USA, where offline Manuka honey sales reached $1.06 million during the year, as well as ongoing presence in Japan, Ireland, and the UAE.

King Honey Receivership and Financial Position

The group’s discontinued King Honey subsidiaries entered receivership and liquidation in July 2025 due to trading difficulties and funding challenges, resulting in a $4.1 million gain on loss of control recognised in FY26. Me Today has no ongoing financial obligations related to King Honey’s debts following its deconsolidation.

At year-end, Me Today reported net assets of $2.51 million, reversing from net liabilities of $2.34 million the previous year, and held cash of $1.83 million. The company’s bank borrowings have been reduced to $2.25 million from a substantially higher level in FY25, reflecting a leaner balance sheet.

Outlook Focuses on Brand Investment and Market Growth

With a strengthened balance sheet and committed capital injection, Me Today is positioned to continue investing in its brand, product innovation, and international market expansion throughout FY27. Priorities include growing market share in New Zealand, maximising the China licensing arrangement, building out the Southeast Asia distribution network, and maintaining an active product development pipeline.

While the company’s ongoing investments have improved financial metrics, the actual impact on future profitability remains to be seen amid competitive market dynamics and execution risks.